Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 218 entries
Sorted by: Best Match Show Resources per page
Emerging therapies for the treatment of osteoporosis.

Journal of mid-life health

Bhutani G, Gupta MC.
PMID: 24672186
J Midlife Health. 2013 Jul;4(3):147-52. doi: 10.4103/0976-7800.118991.

Osteoporosis is a chronic disease of the osseous system characterized by decreased bone strength and increased fracture risk. It is due to an imbalance in the dynamic ongoing processes of bone formation and bone resorption. Currently available osteoporosis therapies...

Cite
Bhutani G, Gupta MC. Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013;4(3):147-52doi: 10.4103/0976-7800.118991.
Bhutani, G., & Gupta, M. C. (2013). Emerging therapies for the treatment of osteoporosis. Journal of mid-life health, 4(3), 147-52. https://doi.org/10.4103/0976-7800.118991
Bhutani, Garima, and Gupta, Mahesh Chander. "Emerging therapies for the treatment of osteoporosis." Journal of mid-life health vol. 4,3 (2013): 147-52. doi: https://doi.org/10.4103/0976-7800.118991
Bhutani G, Gupta MC. Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013 Jul;4(3):147-52. doi: 10.4103/0976-7800.118991. PMID: 24672186; PMCID: PMC3952405.
Copy Download .nbib Format: NLM
Past, present, and future of hormonal therapy in recurrent endometrial cancer.

International journal of women's health

Carlson MJ, Thiel KW, Leslie KK.
PMID: 24833920
Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014.

Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven, typically present with a low grade at an early stage, and are of endometrioid histology. These cancers are often cured by surgery, and the rate of recurrence...

Cite
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429-35doi: 10.2147/IJWH.S40942.
Carlson, M. J., Thiel, K. W., & Leslie, K. K. (2014). Past, present, and future of hormonal therapy in recurrent endometrial cancer. International journal of women's health, 6429-35. https://doi.org/10.2147/IJWH.S40942
Carlson, Matthew J, et al. "Past, present, and future of hormonal therapy in recurrent endometrial cancer." International journal of women's health vol. 6 (2014): 429-35. doi: https://doi.org/10.2147/IJWH.S40942
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014. PMID: 24833920; PMCID: PMC4014387.
Copy Download .nbib Format: NLM
Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.

Biomedicines

Keely NO, Carr M, Yassin B, Ana G, Lloyd DG, Zisterer D, Meegan MJ.
PMID: 28536383
Biomedicines. 2016 Jul 20;4(3). doi: 10.3390/biomedicines4030015.

Nuclear-receptors are often overexpressed in tumours and can thereby be used as targets when designing novel selective chemotherapeutic agents. To date, many conjugates incorporating an estrogen receptor (ER) ligand have been synthesised in order to direct chemical agents to...

Cite
Keely NO, Carr M, Yassin B, et al. Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold. Biomedicines. 2016;4(3)doi: 10.3390/biomedicines4030015.
Keely, N. O., Carr, M., Yassin, B., Ana, G., Lloyd, D. G., Zisterer, D., & Meegan, M. J. (2016). Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold. Biomedicines, 4(3), . https://doi.org/10.3390/biomedicines4030015
Keely, Niall O, et al. "Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold." Biomedicines vol. 4,3 (2016). doi: https://doi.org/10.3390/biomedicines4030015
Keely NO, Carr M, Yassin B, Ana G, Lloyd DG, Zisterer D, Meegan MJ. Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold. Biomedicines. 2016 Jul 20;4(3). doi: 10.3390/biomedicines4030015. PMID: 28536383; PMCID: PMC5344255.
Copy Download .nbib Format: NLM
Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.

SpringerPlus

Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S.
PMID: 24298433
Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013.

Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials investigating the utility of adding fulvestrant to other therapeutics...

Cite
Edavana VK, Penney RB, Yao-Borengasser A, et al. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013;2:620doi: 10.1186/2193-1801-2-620.
Edavana, V. K., Penney, R. B., Yao-Borengasser, A., Williams, S., Rogers, L., Dhakal, I. B., & Kadlubar, S. (2013). Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. SpringerPlus, 2620. https://doi.org/10.1186/2193-1801-2-620
Edavana, Vineetha K, et al. "Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism." SpringerPlus vol. 2 (2013): 620. doi: https://doi.org/10.1186/2193-1801-2-620
Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013. PMID: 24298433; PMCID: PMC3841332.
Copy Download .nbib Format: NLM
Phytoestrogens as hormone replacement therapy: an evidence-based approach.

Primary care update for Ob/Gyns

Carusi D.
PMID: 11077239
Prim Care Update Ob Gyns. 2000 Nov 01;7(6):253-259. doi: 10.1016/s1068-607x(00)00055-x.

Postmenopausal women have sought nonestrogen alternatives to hormone replacement in order to avoid possible risks and side effects of the therapy. Selective estrogen receptor modulators have been developed to tailor therapy to a specific risk/benefit profile that will best...

Cite
Carusi D. Phytoestrogens as hormone replacement therapy: an evidence-based approach. Prim Care Update Ob Gyns. 2000;7(6):253-259doi: 10.1016/s1068-607x(00)00055-x.
Carusi, D. (2000). Phytoestrogens as hormone replacement therapy: an evidence-based approach. Primary care update for Ob/Gyns, 7(6), 253-259. https://doi.org/10.1016/s1068-607x(00)00055-x
Carusi. "Phytoestrogens as hormone replacement therapy: an evidence-based approach." Primary care update for Ob/Gyns vol. 7,6 (2000): 253-259. doi: https://doi.org/10.1016/s1068-607x(00)00055-x
Carusi D. Phytoestrogens as hormone replacement therapy: an evidence-based approach. Prim Care Update Ob Gyns. 2000 Nov 01;7(6):253-259. doi: 10.1016/s1068-607x(00)00055-x. PMID: 11077239.
Copy Download .nbib Format: NLM
Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover.

Drugs of today (Barcelona, Spain : 1998)

Kress BC, Mizrahi IA.
PMID: 12973383
Drugs Today (Barc). 1999 Mar;35(3):181-5. doi: 10.1358/dot.1999.35.3.533847.

Postmenopausal osteoporosis is preventable. An increasing number of antiresorptive therapies including estrogen, selective estrogen receptor modulators (the so-called designer estrogens), bisphosphonates and calcitonins are now available as treatment options for osteoporosis. These agents reduce the level of bone turnover...

Cite
Kress BC, Mizrahi IA. Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover. Drugs Today (Barc). 1999;35(3):181-5doi: 10.1358/dot.1999.35.3.533847.
Kress, B. C., & Mizrahi, I. A. (1999). Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover. Drugs of today (Barcelona, Spain : 1998), 35(3), 181-5. https://doi.org/10.1358/dot.1999.35.3.533847
Kress, B C, and Mizrahi, I A. "Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover." Drugs of today (Barcelona, Spain : 1998) vol. 35,3 (1999): 181-5. doi: https://doi.org/10.1358/dot.1999.35.3.533847
Kress BC, Mizrahi IA. Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover. Drugs Today (Barc). 1999 Mar;35(3):181-5. doi: 10.1358/dot.1999.35.3.533847. PMID: 12973383.
Copy Download .nbib Format: NLM
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.

Current oncology (Toronto, Ont.)

Richardson H, Johnston D, Pater J, Goss P.
PMID: 17593981
Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117.

Several large phase III trials have demonstrated that tamoxifen-and more recently, raloxifene-can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events....

Cite
Richardson H, Johnston D, Pater J, et al. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14(3):89-96doi: 10.3747/co.2007.117.
Richardson, H., Johnston, D., Pater, J., & Goss, P. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current oncology (Toronto, Ont.), 14(3), 89-96. https://doi.org/10.3747/co.2007.117
Richardson, H, et al. "The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial." Current oncology (Toronto, Ont.) vol. 14,3 (2007): 89-96. doi: https://doi.org/10.3747/co.2007.117
Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117. PMID: 17593981; PMCID: PMC1899358.
Copy Download .nbib Format: NLM
Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?.

Nature clinical practice. Oncology

Schiff R, Lee AV.
PMID: 16520802
Nat Clin Pract Oncol. 2006 Mar;3(3):134-5. doi: 10.1038/ncponc0444.

No abstract available.

Cite
Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nat Clin Pract Oncol. 2006;3(3):134-5doi: 10.1038/ncponc0444.
Schiff, R., & Lee, A. V. (2006). Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nature clinical practice. Oncology, 3(3), 134-5. https://doi.org/10.1038/ncponc0444
Schiff, Rachel, and Lee, Adrian V. "Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?." Nature clinical practice. Oncology vol. 3,3 (2006): 134-5. doi: https://doi.org/10.1038/ncponc0444
Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?. Nat Clin Pract Oncol. 2006 Mar;3(3):134-5. doi: 10.1038/ncponc0444. PMID: 16520802.
Copy Download .nbib Format: NLM
[Future prospects for the treatment of osteoporosis].

Clinical calcium

Matsumoto T.
PMID: 15775498
Clin Calcium. 2001 Jan;11(1):87-91. doi: CliCa01018791.

In order to prevent osteoporotic fractures, various drugs with anti-resorptive effects have been developed. These include new generation of bisphosphonates and selective estrogen receptor modulators. There are also agents under development with stimulatory effect on bone formation, including parathyroid...

Cite
Matsumoto T. [Future prospects for the treatment of osteoporosis]. Clin Calcium. 2001;11(1):87-91doi: CliCa01018791.
Matsumoto, T. (2001). [Future prospects for the treatment of osteoporosis]. Clinical calcium, 11(1), 87-91. https://doi.org/CliCa01018791
Matsumoto, T. "[Future prospects for the treatment of osteoporosis]." Clinical calcium vol. 11,1 (2001): 87-91. doi: https://doi.org/CliCa01018791
Matsumoto T. [Future prospects for the treatment of osteoporosis]. Clin Calcium. 2001 Jan;11(1):87-91. doi: CliCa01018791. Japanese. PMID: 15775498.
Copy Download .nbib Format: NLM
CINP 2000. Selective estrogen receptor modulators.

IDrugs : the investigational drugs journal

Moret C.
PMID: 16049860
IDrugs. 2000 Sep;3(9):1026-9.

No abstract available.

Cite
Moret C. CINP 2000. Selective estrogen receptor modulators. IDrugs. 2000;3(9):1026-9
Moret, C. (2000). CINP 2000. Selective estrogen receptor modulators. IDrugs : the investigational drugs journal, 3(9), 1026-9.
Moret, C. "CINP 2000. Selective estrogen receptor modulators." IDrugs : the investigational drugs journal vol. 3,9 (2000): 1026-9.
Moret C. CINP 2000. Selective estrogen receptor modulators. IDrugs. 2000 Sep;3(9):1026-9. PMID: 16049860.
Copy Download .nbib Format: NLM
Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators.

Bioinformation

Salisbury JP, Williams JC.
PMID: 19293997
Bioinformation. 2009;3(7):303-7. doi: 10.6026/97320630003303. Epub 2009 Feb 28.

Virtual high throughput screening (VHTS) was performed to assess possible interactions which might occur between commercially available triphenylphosphonium (TPP) cations and estrogen receptor alpha (ERalpha) that could be exploited to design novel ERalpha modulators. One application of TPP cations...

Cite
Salisbury JP, Williams JC. Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators. Bioinformation. 2009;3(7):303-7doi: 10.6026/97320630003303.
Salisbury, J. P., & Williams, J. C. (2009). Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators. Bioinformation, 3(7), 303-7. https://doi.org/10.6026/97320630003303
Salisbury, Joseph P, and Williams, John C. "Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators." Bioinformation vol. 3,7 (2009): 303-7. doi: https://doi.org/10.6026/97320630003303
Salisbury JP, Williams JC. Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators. Bioinformation. 2009;3(7):303-7. doi: 10.6026/97320630003303. Epub 2009 Feb 28. PMID: 19293997; PMCID: PMC2655049.
Copy Download .nbib Format: NLM
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

Clinical medicine. Therapeutics

Milani M, Jha G, Potter DA.
PMID: 19794821
Clin Med Ther. 2009 Mar 31;1:141-156. doi: 10.4137/cmt.s9.

The majority of breast cancers express the estrogen receptor and depend on estradiol (E2) for their growth. Hormonal therapy aims at depriving estrogen signaling either by using selective estrogen receptor modulators (SERM)-that interfere with the binding of E2 to...

Cite
Milani M, Jha G, Potter DA. Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther. 2009;1:141-156doi: 10.4137/cmt.s9.
Milani, M., Jha, G., & Potter, D. A. (2009). Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clinical medicine. Therapeutics, 1141-156. https://doi.org/10.4137/cmt.s9
Milani, Monica, et al. "Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women." Clinical medicine. Therapeutics vol. 1 (2009): 141-156. doi: https://doi.org/10.4137/cmt.s9
Milani M, Jha G, Potter DA. Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther. 2009 Mar 31;1:141-156. doi: 10.4137/cmt.s9. PMID: 19794821; PMCID: PMC2753667.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 218 entries